In 381 adults with moderate-to-severe COPD at high exacerbation risk, mitiperstat 5 mg daily for up to 24 weeks did not delay first COPDCompEx event vs placebo (66.1% vs 65.1%; HR 1.07, 90% CI 0.87–1.32). Pneumonia occurred in 7 vs 2 participants.
RCTn = 381
Saralaya et al. A phase 2a, double-blind, randomised, placebo-controlled trial of the myeloperoxidase inhibitor, mitiperstat, in participants with COPD